Rosalvo Zósimo Bispo Júnior
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Rosalvo Zósimo Bispo Júnior has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Olavo Pires de Camargo
Universidade de São Paulo
4 shared publications Alexandre Vieira Guedes
CEMKA
2 shared publicationsAndré Mathias Baptista
Universidade de São Paulo, Brazil
2 shared publicationsAlexandre Takayuki Soejima
Kawano Policlinic, Sao Paulo, Brazil
1 shared publicationCezar Teruyuki Kawano
CEMKA
1 shared publicationCláudia Regina G. C. M. De Oliveira
São Paulo University Medical School HC
1 shared publication
Latest Publications
- Open Access
- 1 January 2011
- Published by Georg Thieme Verlag KG in Revista Brasileira de Ortopedia
- Vol. 46 (4) , 420-423
Existe diferença no prognóstico de pacientes com osteossarcoma primário com uma pobre resposta à quimioterapia neoadjuvante entre os graus I e II de huvos?
OBJETIVO: Haveria diferença no prognóstico de pacientes que apresentam, por exemplo, 8% ou 88% de necrose tumoral induzida pela quimioterapia, apesar de ambos serem considerados maus respondedores? O objetivo deste estudo foi comparar o prognóstico da graduação histológica (grau I versus II de Huvos) após efeito quimioterápico nos pacientes portadores de osteossarcoma primário, não metastático ao diagnóstico. MÉTODOS: Vinte e quatro pacientes admitidos em um serviço de referência entre 2000 e 2004 foram eleitos para o estudo. As probabilidades de sobrevida acumuladas foram feitas pela técnica de Kaplan-Meier. Os índices I e II de Huvos, para o grau de necrose após efeito quimioterápico, foram avaliados como variáveis para determinação de seu valor prognóstico em relação à sobrevida livre de recidiva local, sobrevida livre de metástases e sobrevida global, utilizando-se o teste Log-Rank. RESULTADOS: Quando comparados, os graus I e II de Huvos atingiram os seguintes valores de P nas sobrevidas estudadas: sobrevida livre de recidiva local (P = 0,731), sobrevida livre de metástases (P = 0,596) e sobrevida global (P = 0,669). CONCLUSÃO: Nesta série, os graus I e II de Huvos, comparativamente, não são de valor prognóstico, comportando-se de forma semelhante.OBJECTIVE: Would there be any difference in the prognosis for patients who presented, for example, 8% or 88% tumor necrosis induced by chemotherapy, even though both individuals were considered to be poor responders? The aim of this study was to compare the prognoses for different histological grades (Huvos grade I versus grade II), consequent to chemotherapy, among patients with primary osteosarcoma that was not metastatic at diagnosis. METHODS: Twenty-four patients admitted to a referral center between 2000 and 2004 were selected for the study. The accumulated chances of survival were calculated using the Kaplan-Meier technique. Huvos grades I and II for necrosis consequent to chemotherapy were evaluated as variables in order to determine their prognostic value, in relation to local recurrence-free survival, metastasis-free survival and overall survival, using the log-rank test. RESULTS: Comparing Huvos grades I and II, the following P values for survival were attained: local recurrence-free survival (P = 0.731), metastasis-free survival (P = 0.596) and overall survival (P = 0.669). CONCLUSION: In this series, Huvos grades I and II did not have any comparative prognostic value and had similar behavior
- 1 January 2011
- Published by Georg Thieme Verlag KG in Revista Brasileira de Ortopedia
- Vol. 46 (4) , 420-423
Open AccessExiste diferença no prognóstico de pacientes com osteossarcoma primário com uma pobre resposta à quimioterapia neoadjuvante entre os graus I e II de huvos?
OBJETIVO: Haveria diferença no prognóstico de pacientes que apresentam, por exemplo, 8% ou 88% de necrose tumoral induzida pela quimioterapia, apesar de ambos serem considerados maus respondedores? O objetivo deste estudo foi comparar o prognóstico da graduação histológica (grau I versus II de Huvos) após efeito quimioterápico nos pacientes portadores de osteossarcoma primário, não metastático ao diagnóstico. MÉTODOS: Vinte e quatro pacientes admitidos em um serviço de referência entre 2000 e 2004 foram eleitos para o estudo. As probabilidades de sobrevida acumuladas foram feitas pela técnica de Kaplan-Meier. Os índices I e II de Huvos, para o grau de necrose após efeito quimioterápico, foram avaliados como variáveis para determinação de seu valor prognóstico em relação à sobrevida livre de recidiva local, sobrevida livre de metástases e sobrevida global, utilizando-se o teste Log-Rank. RESULTADOS: Quando comparados, os graus I e II de Huvos atingiram os seguintes valores de P nas sobrevidas estudadas: sobrevida livre de recidiva local (P = 0,731), sobrevida livre de metástases (P = 0,596) e sobrevida global (P = 0,669). CONCLUSÃO: Nesta série, os graus I e II de Huvos, comparativamente, não são de valor prognóstico, comportando-se de forma semelhante.OBJECTIVE: Would there be any difference in the prognosis for patients who presented, for example, 8% or 88% tumor necrosis induced by chemotherapy, even though both individuals were considered to be poor responders? The aim of this study was to compare the prognoses for different histological grades (Huvos grade I versus grade II), consequent to chemotherapy, among patients with primary osteosarcoma that was not metastatic at diagnosis. METHODS: Twenty-four patients admitted to a referral center between 2000 and 2004 were selected for the study. The accumulated chances of survival were calculated using the Kaplan-Meier technique. Huvos grades I and II for necrosis consequent to chemotherapy were evaluated as variables in order to determine their prognostic value, in relation to local recurrence-free survival, metastasis-free survival and overall survival, using the log-rank test. RESULTS: Comparing Huvos grades I and II, the following P values for survival were attained: local recurrence-free survival (P = 0.731), metastasis-free survival (P = 0.596) and overall survival (P = 0.669). CONCLUSION: In this series, Huvos grades I and II did not have any comparative prognostic value and had similar behavior
- Open Access
- 1 September 2009
- Published by FapUNIFESP (SciELO) in Sao Paulo Medical Journal
- Vol. 127 (5) , 310-313
Primary malignancy in giant cell tumor: a case report
CONTEXT: Primary malignancy in giant cell tumor (PMGCT) is rare. It is defined as a high-grade sarcoma originating in a giant cell tumor (GCT) and seems to behave less aggressively than its secondary counterpart does. CASE REPORT: This report presents the case of a 39-year-old female with pain in her left shoulder for one month. Radiography showed a pathological fracture of the proximal humerus associated with an osteolytic lesion. Histopathological analysis showed typical areas of GCT juxtaposed with a sarcomatous component. CONCLUSIONS: PMGCT seems to behave less aggressively than secondary malignancy in GCT, and it may simulate its more common benign counterpart clinically and radiographically. However, it requires a more aggressive type of treatment.
- 1 September 2009
- Published by FapUNIFESP (SciELO) in Sao Paulo Medical Journal
- Vol. 127 (5) , 310-313
Open AccessPrimary malignancy in giant cell tumor: a case report
CONTEXT: Primary malignancy in giant cell tumor (PMGCT) is rare. It is defined as a high-grade sarcoma originating in a giant cell tumor (GCT) and seems to behave less aggressively than its secondary counterpart does. CASE REPORT: This report presents the case of a 39-year-old female with pain in her left shoulder for one month. Radiography showed a pathological fracture of the proximal humerus associated with an osteolytic lesion. Histopathological analysis showed typical areas of GCT juxtaposed with a sarcomatous component. CONCLUSIONS: PMGCT seems to behave less aggressively than secondary malignancy in GCT, and it may simulate its more common benign counterpart clinically and radiographically. However, it requires a more aggressive type of treatment.
- Open Access
Prognostic Factors and Expression of MDM2 in Patients with Primary Extremity Liposarcoma
- Open Access
Chronic Multiple Knee Ligament Injuries: Epidemiological Analysis of More Than One Hundred Cases